Johnson & Johnson (JNJ) Restructuring Costs (2010 - 2026)
Johnson & Johnson recorded quarterly Restructuring Costs of $32.0 million in Q1 2026, down 61.9% quarter-over-quarter from $84.0 million in Q4 2025, and up 88.24% year-over-year from $17.0 million in Q1 2025.
Johnson & Johnson's Restructuring Costs history runs 14 years deep, the most recent figure standing at $32.0 million for Q1 2026.
- In Q1 2026, Restructuring Costs rose 88.24% year-over-year to $32.0 million; the TTM figure through Mar 2026 stood at $243.0 million (up 179.31% YoY), while the FY2025 annual figure was $228.0 million, down 2.56% from the prior year.
- Restructuring Costs came in at $32.0 million for Q1 2026 at Johnson & Johnson, down from $84.0 million in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $164.0 million in Q1 2024 to a low of -$13.0 million in Q2 2024.
- A 5-year average of $77.0 million and a median of $65.0 million in 2022 frame the typical range for Restructuring Costs.
- Across the five-year window, Restructuring Costs slumped 108.97% in 2024 and surged 592.31% in 2025, its largest moves.
- Johnson & Johnson's Restructuring Costs stood at $65.0 million in 2022, then decreased by 13.85% to $56.0 million in 2023, then fell by 25.0% to $42.0 million in 2024, then jumped by 100.0% to $84.0 million in 2025, then tumbled by 61.9% to $32.0 million in 2026.
- According to Business Quant data, Restructuring Costs over the past three periods registered $32.0 million, $84.0 million, and $63.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 32.00 Mn |
| Dec 28, 2025 | 84.00 Mn |
| Sep 28, 2025 | 63.00 Mn |
| Jun 29, 2025 | 64.00 Mn |
| Mar 30, 2025 | 17.00 Mn |
| Dec 29, 2024 | 42.00 Mn |
| Sep 29, 2024 | 41.00 Mn |
| Jun 30, 2024 | -13.00 Mn |
| Mar 31, 2024 | 164.00 Mn |
| Dec 31, 2023 | 56.00 Mn |
| Oct 1, 2023 | 158.00 Mn |
| Jul 2, 2023 | 145.00 Mn |
| Apr 2, 2023 | 130.00 Mn |
| Jan 1, 2023 | 106.00 Mn |
| Oct 2, 2022 | 65.00 Mn |
| Jul 3, 2022 | 85.00 Mn |
| Apr 3, 2022 | 70.00 Mn |
| Oct 3, 2021 | 60.00 Mn |
| Jul 4, 2021 | 56.00 Mn |
| Apr 4, 2021 | 53.00 Mn |
| Jan 3, 2021 | 60.00 Mn |
| Sep 27, 2020 | 68.00 Mn |
| Jun 28, 2020 | 61.00 Mn |
| Mar 29, 2020 | 58.00 Mn |
| Dec 29, 2019 | 251.00 Mn |
| Sep 29, 2019 | 69.00 Mn |
| Jun 30, 2019 | 57.00 Mn |
| Mar 31, 2019 | 36.00 Mn |
| Dec 30, 2018 | 227.00 Mn |
| Sep 30, 2018 | 190.00 Mn |
| Jul 1, 2018 | 176.00 Mn |
| Apr 1, 2018 | 107.00 Mn |
| Dec 31, 2017 | 284.00 Mn |
| Oct 1, 2017 | 187.00 Mn |
| Jul 2, 2017 | 128.00 Mn |
| Apr 2, 2017 | 161.00 Mn |
| Jan 1, 2017 | 298.00 Mn |
| Oct 2, 2016 | 109.00 Mn |
| Jul 3, 2016 | 141.00 Mn |
| Apr 3, 2016 | 137.00 Mn |
| Jan 3, 2016 | 590.00 Mn |
| Dec 30, 2012 | -589.00 Mn |
| Jul 3, 2011 | 589.00 Mn |
| Jan 3, 2010 | 1.20 Bn |